๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumor
Clinical trial register · China

Advanced Solid Tumor Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 63 Shanghai 52 Guangzhou 40 Hangzhou 19 Fuzhou 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines11 Suzhou Zelgen Biopharmaceuticals Co.,Ltd4 LaNova Medicines Limited4 MediLink Therapeutics (Suzhou) Co., Ltd.4 Daiichi Sankyo4
Site location
Beijing63 Shanghai52 Guangzhou40 Hangzhou19 Fuzhou19
All 68 locations
Target enrolment
to

Advanced Solid Tumor trials in China

159 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
NCT05879822Advanced Solid Tumor
Incyte Corporation
Phase 2
73
Nanning
2023-10-30
Active, closed
A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
NCT06143007Advanced Solid Tumor
Broadenbio Ltd., Co.
Phase 1
42
Beijing
2023-10-26
Recruiting
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
NCT06225856Advanced Solid Tumor, Hematological Malignancy
Shanghai Yuyao Biotech Co., Ltd.
Phase 1
96
Shanghai
2023-10-26
Recruiting
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPฮฑ-CD47 Pathway, in Solid or Hematological Tumors
NCT05892718Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
FBD Biologics Limited
Phase 1
80
Hangzhou
2023-10-02
Recruiting
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
NCT06072989Advanced Solid Tumor
Shanghai East Hospital
Phase 1
24
Shanghai
2023-10
Active, closed
A Study YL201 in Patients With Selected Advanced Solid Tumors
NCT06057922Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Active, closed
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
NCT05990452Advanced Solid Tumor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
261
Shanghai
2023-08-28
Recruiting
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
NCT05978102Advanced Solid Tumor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2
183
Yiwu
2023-08-23
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Beijing, Jinan, Neijiang, Shanghai
2023-08-18
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Recruiting
A Study of BA1202 in Patients With Advanced Solid Tumors
NCT05909241Advanced Solid Tumor
Shandong Boan Biotechnology Co., Ltd
Phase 1
78
Beijing
2023-08-16
Recruiting
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
NCT06038396Advanced Solid Tumor
RemeGen Co., Ltd.
Phase 1/2
48
Fuzhou, Xiamen, Wuwei, Meizhou, Harbin, Nanyang, Xinyang, Zhengzhou
2023-08-03
Recruiting
A Study of EOC237 in Patients With Advanced Solid Tumor
NCT05895825Advanced Solid Tumor
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Phase 1
48
Beijing
2023-07-26
Active, closed
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
NCT05700084Advanced Solid Tumor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
NCT06302062Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
23
Guangzhou
2023-06-06
Active, closed
A Study of MHB036C for Advanced Solid Tumor
NCT06373406Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Shanghai
2023-05-26
Recruiting
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
NCT05836948Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
174
Hangzhou
2023-05-18
Recruiting
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Recruiting
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
NCT05103345Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Chengdu
2023-04-19
Active, closed
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
NCT06299124Breast Cancer, Advanced Solid Tumor
Regor Pharmaceuticals Inc.
Phase 1
40
Shanghai
2023-04-17
Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
30
Shanghai
2023-04-01
Not yet open
A Study of KM602 in Patients With Advanced Solid Tumors
NCT05766527Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
38
Beijing
2023-04
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Active, closed
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427Advanced Solid Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Haโ€™erbin, Hefei, Jinan
2023-03-15
Recruiting
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
NCT05911464Advanced Solid Tumor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
248
Shanghai
2023-03-02
Recruiting
Study of SGN1 in Patients With Advanced Solid Tumor
NCT05038150Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Shanghai, Chengdu
2023-01-16
Recruiting
TR64 in Patients With Advanced Solid Tumors
NCT05649345Advanced Solid Tumor
Tarapeutics Science Inc.
Phase 1
19
Bengbu, Shenyang
2023-01-12
Active, closed
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
NCT05765032Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
220
Tianjin
2022-12-30
Recruiting
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
NCT06258408Advanced Solid Tumor
Broadenbio Ltd., Co.
Phase 1
78
Guangzhou, Zhengzhou
2022-12-29
Recruiting
Study of ZGGS18 in Patients With Advanced Solid Tumors
NCT05584800Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
222
Beijing
2022-11-15
Recruiting
HEC169096 in Participants With Advanced Solid Tumors
NCT05451602Advanced Solid Tumor
Sunshine Lake Pharma Co., Ltd.
Phase 1/2
456
Guangzhou
2022-10-21
Active, closed
A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors
NCT05621486Advanced Solid Tumor
Shanghai East Hospital
Phase 1
36
Shanghai
2022-09-14
Recruiting
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT05341557Advanced Solid Tumor, Lymphoma, NSCLC, HCC
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Active, closed
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
NCT05518045Advanced Solid Tumor
LaNova Medicines Limited
Phase 1/2
392
Beijing
2022-08-26
Recruiting
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321Advanced Solid Tumor, NSCLC
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Jinan
2022-08-25
Recruiting
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
NCT05306132Advanced Solid Tumor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
150
Zhengzhou, Changsha, Shanghai
2022-08-08
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Recruiting
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
NCT05487170Advanced Solid Tumor, DLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
32
Beijing
2022-07-12
Recruiting
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
NCT05367778Advanced Solid Tumor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1/2
176
Wuhan
2022-06-03
Recruiting
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT05518253Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
Weijia Fang, MD
Phase 1
30
Hangzhou
2022-05-30
Recruiting
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
NCT05315167Advanced Solid Tumor, Advanced Solid Malignancies
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2
267
Zhengzhou, Chengdu, Hangzhou, Beijing
2022-05-30
Recruiting
A Study of YL201 in Patients With Advanced Solid Tumors
NCT05434234Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
Guangzhou, Zhengzhou
2022-05-25
Recruiting
A Study of CM350 in Patients With Advanced Solid Tumors
NCT05263960Advanced Solid Tumor
Keymed Biosciences Co.Ltd
Phase 1/2
248
Chengdu, Shanghai
2022-04-21
Active, closed
A Study of ILB2109 in Patients With Advanced Solid Malignancies
NCT05278546Advanced Solid Tumor
Innolake Biopharm
Phase 1
48
Jinan, Shanghai
2022-04-11
Not yet open
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
NCT05320874Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
232
Beijing
2022-04
Recruiting
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
NCT05205850Advanced Solid Tumor
RemeGen Co., Ltd.
Phase 1/2
135
Shanghai, Hangzhou
2022-03-03
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
NCT05269316Solid Tumor, Advanced Solid Tumor
Impact Therapeutics, Inc.
Phase 1/2
61
Beijing
2022-02-11
Recruiting
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
NCT05170958Advanced Solid Tumor
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Recruiting
A Study of HS-20089 in Patients With Advanced Solid Tumors
NCT05263479Advanced Solid Tumor
Shanghai Hansoh Biomedical Co., Ltd
Phase 1
177
Shanghai
2022-01-05
Recruiting
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
NCT05087745Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
50
Hangzhou
2021-12-10
Recruiting
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
NCT05142423Advanced Solid Tumor
Akeso
Phase 1/2
198
Hangzhou
2021-11-03
Recruiting
A Study of HG381 Administered to Patients With Advanced Solid Tumors
NCT04998422Advanced Solid Tumor
HitGen Inc.
Phase 1
57
Chengdu
2021-10-18
Recruiting
First in Human, Dose Escalation Study of AN4005
NCT04999384Advanced Solid Tumor, Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.
Phase 1
31
Beijing, Harbin, Wuhan
2021-09-27
Active, closed
A Study of KL590586 in Patients With Advanced Solid Tumors
NCT05265091Advanced Solid Tumor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
414
Chengdu
2021-09-15
Recruiting
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
NCT04785196Liposarcoma, Advanced Solid Tumor
Ascentage Pharma Group Inc.
Phase 1/2
95
Guangzhou, Hangzhou, Shanghai
2021-05-26
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Recruiting
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
NCT04093466Advanced Solid Tumor
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 1
126
Beijing
2020-04-27
Recruiting
A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors
NCT06632574Advanced Solid Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
60
Nanjing
2014-03-19
Rows per page Showing 101–159 of 159
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-solid-tumor?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 159 of those studies listing the condition Advanced Solid Tumor.

How many Advanced Solid Tumor trials are recruiting in China?

124 of the 159 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 23 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.